Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 262

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy

Open access
Huguenin, Pia, Beer, Karl T., Allal, Abdelkarim, Rufibach, Kaspar, Friedli, Corinne, Davis, Jacques Bernard, Pestalozzi, Bernhard, Schmid, Stephan, Thöni, Armin, Ozsahin, Mahmut, Bernier, Jacques, Töpfer, Michael, Kann, Roger, Meier, Urs Richard, Thum, Peter, Bieri, Sabine, Notter, Markus, Lombriser, Norbert, Glanzmann, Christoph · 2004 · Journal of Clinical Oncology

Abstract

Purpose: To determine whether the application of two courses of cisplatin simultaneously with hyperfractionated radiotherapy improves the outcome in locally advanced and/or node-positive nonmetastatic carcinomas of the head and neck, compared with hyperfractionated radiotherapy alone. Patients and Methods: From July 1994 to July 2000, 224 patients with squamous cell carcinomas of the head and neck (excluding nasopharynx and paranasal sinus) were randomly assigned to hyperfractionated radiotherapy (median dose, 74.4 Gy; 1.2 Gy twice daily) or the same radiotherapy combined with two cycles of concomitant cisplatin (20 mg/m 2 on 5 days of weeks 1 and 5). The primary end point was time to any treatment failure; secondary end points were locoregional failure, metastatic relapse, overall survival, and late toxicity. Results: There was no difference in radiotherapy between both treatment arms (74.4 Gy in 44 days). The full cisplatin dose was applied in 93% and 71% of patients during the first and second treatment cycles, respectively. Acute toxicity was similar in both arms. Median time to any treatment failure was not significantly different between treatment arms (19 months for combined treatment and 16 months for radiotherapy only, respectively) and the failure-free rate at 2.5 years was 45% and 33%, respectively. Locoregional control and distant disease–free survival were significantly improved with cisplatin (log-rank test, P = .039 and .011, respectively). The difference in overall survival did not reach significance (log-rank test, P = .147). Late toxicity was comparable in both treatment groups. Conclusion: The therapeutic index of hyperfractionated radiotherapy is improved by concomitant cisplatin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2004.12.193

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 262

Metadata

Authors
Huguenin, P., Beer, K. T., Allal, A., Rufibach, K., Friedli, C., Davis, J. B., Pestalozzi, B., Schmid, S., Thöni, A., Ozsahin, M., Bernier, J., Töpfer, M., Kann, R., Meier, U. R., Thum, P., Bieri, S., Notter, M., Lombriser, N., & Glanzmann, C.
Venue
Journal of Clinical Oncology
Published
2004-12-01
Volume
22
Issue
23
Pages
4665-4673
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2113541736
Cited by
262
References
13
FWCI
16.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy. https://app.cochat.ai/papers/10.1200/jco.2004.12.193
The paper
Huguenin, P., Beer, K. T., Allal, A., Rufibach, K., Friedli, C., Davis, J. B., Pestalozzi, B., Schmid, S., Thöni, A., Ozsahin, M., Bernier, J., Töpfer, M., Kann, R., Meier, U. R., Thum, P., Bieri, S., Notter, M., Lombriser, N., & Glanzmann, C. (2004). Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.12.193

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.